Document Detail


Sustained effects of recombinant GH replacement after 7 years of treatment in adults with GH deficiency.
MedLine Citation:
PMID:  17062886     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
CONTEXT: The goal of GH replacement with recombinant human GH (rhGH) is to ameliorate symptoms, signs, and complications of adult GH deficiency (GHD) in the long term. To determine whether the observed short-term beneficial effects of rhGH treatment are sustained in the long term, we evaluated biochemical and anthropometric parameters after 7 years of rhGH replacement. PATIENTS AND METHODS: After 2, 5, and 7 years of rhGH replacement, 63 adult GHD patients (30 men, 52 adult-onset GHD) were assessed. IGF-I increased during rhGH replacement, and a stable dose of rhGH was reached within 1 year of rhGH substitution. Thereafter, this individualized dose was continued. RESULTS: Plasma levels of total cholesterol and low-density lipoprotein cholesterol decreased even after 5 years of rhGH replacement (11% decrease, P < 0.001; 22% decrease, P < 0.001 respectively). High-density lipoprotein cholesterol levels increased during 7 years of rhGH replacement (1.4 +/- 0.5 mmol/l at baseline vs 1.7 +/- 0.5 mmol/l after 7 years, P < 0.001), whereas triglyceride concentrations remained unchanged. Fasting glucose levels increased during follow-up, mainly during the first 2 years of rhGH replacement (4.4 +/- 0.7 mmol/l to 5.0 +/- 1.0 mmol/l, P < 0.001). Body mass index increased during follow-up, whereas waist circumference and waist-to-hip ratio remained unchanged. Diastolic blood pressure decreased (P = 0.002), but when patients using antihypertensive medication were excluded this decrease did not reach significance (P = 0.064). Systolic blood pressure remained unchanged. CONCLUSION: The beneficial effects of rhGH replacement, described after short-term rhGH replacement, are sustained in the long term up to 7 years.
Authors:
A A van der Klaauw; J A Romijn; N R Biermasz; J W A Smit; J van Doorn; O M Dekkers; F Roelfsema; A M Pereira
Related Documents :
22725706 - Position of indapamide, a diuretic with vasorelaxant activities, in antihypertensive th...
1596306 - Microalbuminuria and associated cardiovascular risk factors in the community.
8533746 - Spouse correlations in cardiovascular risk factors and the effect of marriage duration.
8324436 - Effectiveness of programme for reducing cardiovascular risk for men in one general prac...
6111636 - Pressor effect of naloxone in septic shock.
8223806 - The effect of variations in positive end expiratory pressure on gas exchange in ventila...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  European journal of endocrinology / European Federation of Endocrine Societies     Volume:  155     ISSN:  0804-4643     ISO Abbreviation:  Eur. J. Endocrinol.     Publication Date:  2006 Nov 
Date Detail:
Created Date:  2006-10-25     Completed Date:  2007-01-08     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9423848     Medline TA:  Eur J Endocrinol     Country:  England    
Other Details:
Languages:  eng     Pagination:  701-8     Citation Subset:  IM    
Affiliation:
Department of Endocrinology and Metabolic Diseases C4-R, Leiden University Medical Center, Po Box 9600, 2300 RC, Leiden, The Netherlands. a.a.van_der_klaauw@lumc.nl
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Age Factors
Blood Glucose / metabolism
Body Mass Index
Cholesterol / blood
Cholesterol, HDL / blood
Cholesterol, LDL / blood
Fasting / blood
Female
Follow-Up Studies
Human Growth Hormone / deficiency,  therapeutic use*
Humans
Male
Middle Aged
Prospective Studies
Recombinant Proteins / therapeutic use
Sex Factors
Treatment Outcome
Chemical
Reg. No./Substance:
0/Blood Glucose; 0/Cholesterol, HDL; 0/Cholesterol, LDL; 0/Recombinant Proteins; 12629-01-5/Human Growth Hormone; 57-88-5/Cholesterol

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Biochemical markers of bone turnover and their relation to forearm bone mineral density in persons o...
Next Document:  Serum GH and IGF-I are significant determinants of bone turnover but not bone mineral density in act...